Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00587483 · ClinicalTrials.gov registry record · NA
Amiodarone for the Prevention of Reperfusion Ventricular Fibrillation
A NA study, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 342
- Enrollment target
NCT00587483: Completed NA study, sponsored by Mayo Clinic.
NCT00587483 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 342 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (76% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00587483, a NA study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 342 participants
- Enrollment target
Study Summary
This was a prospective, randomized, double blinded study in which patients undergoing a cardiopulmonary bypass (CPB) with aortic cross clamping were randomly assigned to receive amiodarone, lidocaine, or saline placebo prior to removal of the aortic cross clamp. (CPB is a technique that temporarily takes over the function of the heart and lungs during surgery, maintaining the circulation of blood and the oxygen content of the body.) Specifically, we will test the hypothesis that amiodarone is superior to both lidocaine and placebo in the prevention of a severely abnormal heart rhythm when the blood flow is restored to the heart after the aortic cross clamp is removed.
Interventions
- DRUG Placebo
- DRUG Lidocaine
- DRUG Amiodarone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 342 participants |
| Start Date | 2007-11 |
| Est. Completion | 2010-01 |
| Phase | NA |
What the finished NCT00587483 record still lists
NCT00587483 is an interventional study that assigns participants to a tested intervention. The registered 342 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (76% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00587483 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00587483 about?
NCT00587483 is a clinical study titled "Amiodarone for the Prevention of Reperfusion Ventricular Fibrillation". This was a prospective, randomized, double blinded study in which patients undergoing a cardiopulmonary bypass (CPB) with aortic cross clamping were randomly assigned to receive amiodarone, lidocaine, or saline placebo prior to removal of the aortic cross clamp. (CPB is a technique that temporarily ...
What is the current status of trial NCT00587483?
This trial is currently completed. It is a NA study. The enrollment target is 342 participants. The study started on 2007-11. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00587483?
The interventions under investigation include: Placebo (DRUG), Lidocaine (DRUG), Amiodarone (DRUG).
Who is sponsoring clinical trial NCT00587483?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00587483's enrollment target sits among peer trials
342 302nd of 2000 higher than 1,699 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05283850 · 342 participants · Phase 2
Surviving PEA in Roanoke (SPEAR) Study
- NCT05714085 · 342 participants · Phase 2
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
- NCT06188702 · 342 participants · Phase 1
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
- NCT06544941 · 342 participants · NA
Improving Maternal Sleep and Mental Health
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia